April 8 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON ANNOUNCES POSITIVE FEEDBACK FROM HEALTH CANADA FOR IFENPRODIL COVID-19 PHASE 2 HUMAN TRIAL
* ALGERNON PHARMACEUTICALS INC - COMPANY PLANS TO SUBMIT CTA TO HEALTH CANADA FOR APPROVAL OF PHASE 2 CLINICAL TRIAL WITHIN NEXT WEEK